Indication:
Lactobacillus brevis CD2 Lozenges 100mg (corresponding to not
less than 1 billion ) of live,lyophilised ,lactic acid bacteria,
Lactobacillus brevis Cd2 .( Additional indication)
Indication-
Prevention of radiotherapy and chemotherapy induced oral mucositis
in cancer patients
Approved by FDA on 08-09-2014 (Ref- FDA approved List- 2014)
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Lactobacillus Brevis CD2 09-08-2014
Lozenges 100mg 9corresponding
to not less than 1 Billion) of live
Lyopilised Lactic acid Baceria,
Lactobaccilus Brevis CD2
(Addl.Indn.)
Prevention of Radiotherapy and chemotherapy induced oral
mucositis in cancer patients
2.Lactobacillus Rhammnosus 04-11-2009
1 Billion Cells + Saccharomyces
Boulardi 125mg + Zinc enriched
yeast 20mg Sachets & capsules
For the treatment of acute diarrhoea in children
3 Strptococcus thermophilus 45% + 01-08-2007
Bafidobacteria (B.Longum B.infants,B.breve ) 45% +
Lactobacillus acidophillus 3% +
Lactobacillus casel 2% +
Lactobacillus delbrueck susp 3%
Bulgari 2% +
Lactobacillus plantarum
For management of rotavirus diarrhoea in children
4 Streptococcus thermophillus 45%w/w + 31-01-2008
Bifidobacteria (B.longum, b.infantis, b.breve ) 45%+
Lactobacillus acidophillus 3%w/w +
Lactobacillus casei 2% w/w +
Lactobacillus delbrucki susp
Bulgaris 3% w/w +
Lactobacillus plantarum 2% w/w capsules
For the treatment of irritable bowel syndrome
Manufacturer Details